Subtype
Malignant Male Reproductive System Neoplasm
CI-CAN-00003180Explore in graph →
1,451 active trials27 approved drugs58 evidence items
- NCIt
- C8561
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003180Explore in graph →
Clinical trials
6,227 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (762)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06470685 | Prophylactic Prostatectomy for Prostate Cancer (PPPC)(PPPC) | enrolling by invitation | — | 20 | Royal Marsden NHS Foundation TrustOTHER | 1 | Mar 27, 2025 | clinicaltrials |
| NCT06890832 | A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer | not yet recruiting | Phase 2 | 75 | Jina Pharmaceuticals Inc.INDUSTRY | 0 | Mar 24, 2025 |
| clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06875297 | A Single-center Prospective Interventional Study on FPG500 in Non-metastatic Prostate Cancer Patients | not yet recruiting | N/A | 184 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT04794777 | Comparing "Salvage" Radiotherapy and Individualized PSMA PET/CT Targeted Treatment in With Relapsing Prostate Cancer | recruiting | Phase 3 | 450 | Stefan CarlssonOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT05169112 | Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy | recruiting | Phase 3 | 72 | Ottawa Hospital Research InstituteOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT03525288 | PSMA-PET Guided Radiotherapy(PSMA-PETgRT) | active not recruiting | Phase 2 / Phase 3 | 130 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT04100174 | Focal HDR Brachytherapy Boost to Stereotactic Radiotherapy(fBTsRT) | recruiting | Phase 2 | 150 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT04557501 | PSMA PET/CT Guided Intensification of Therapy in Patients at Risk of Advanced Prostate Cancer(PATRON) | active not recruiting | Phase 3 | 800 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT06505356 | Characterization of Microbiological and Genetic Features in Prostate Cancer and Their Association with Disease Stage | enrolling by invitation | N/A | 400 | Edgaras BurzinskisOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT05523856 | New Treatment Modalities for Localized Prostate Cancer(TTOPROST/OBS) | active not recruiting | — | 480 | Fundacion IMIMOTHER | 0 | Mar 12, 2025 | clinicaltrials |
| NCT06652607 | PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer(PSA-DEEP02) | recruiting | — | 152 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06863090 | In Vivo Dosimetry for Brachytherapy Study | recruiting | — | 20 | East and North Hertfordshire NHS TrustOTHER_GOV | 1 | Mar 11, 2025 | clinicaltrials |
| NCT06866782 | European Registry of Next Generation Imaging in Advanced Prostate Cancer(RING) | recruiting | — | 600 | Fundacio PuigvertOTHER | 8 | Mar 11, 2025 | clinicaltrials |
| NCT03987633 | EMPOWER-1: A Multi-site Clinical Cohort Research Study to Reduce Health Inequality(EMPOWER) | recruiting | — | 200,000 | Future Genetics LimitedOTHER | 1 | Mar 10, 2025 | clinicaltrials |
| NCT06866795 | Phase 1 Clinical Study of GT-220F in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC) | not yet recruiting | Phase 1 | 42 | Geode Therapeutics Inc.INDUSTRY | 0 | Mar 10, 2025 | clinicaltrials |
| NCT06864572 | [68Ga]Ga-P17-079 in the Diagnosis and Treatment of Metastatic Prostate Cancer | enrolling by invitation | Early Phase 1 | 40 | Peking Union Medical College HospitalOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06446401 | The Case of "Triple" Versus "Double" Therapy for Patients With High Volume Metastatic Hormone Sensitive Prostate Cancer(Lead4Care) | recruiting | — | 1,400 | Uppsala UniversityOTHER | 1 | Mar 4, 2025 | clinicaltrials |
| NCT06565247 | Evaluation of PSMA-PET and mpMRI in High-risk Prostate Cancer - Using Histopathologic Validation | recruiting | Phase 3 | 60 | Region VästerbottenOTHER_GOV | 1 | Mar 4, 2025 | clinicaltrials |
| NCT06855589 | Optimal Duration of Hormonal Therapy for Unfavorable Intermediate-risk Prostate Cancer Patients: 6 Versus 12 Months.(PCS-XII) | not yet recruiting | Phase 3 | 400 | Charles LeMoyne HospitalOTHER | 1 | Mar 4, 2025 | clinicaltrials |
| NCT01492751 | Effectiveness of Localized Prostate Cancer Treatments(E-PROSTCaT) | active not recruiting | — | 500 | Fundacion IMIMOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT06783829 | A Study of SHR-4394 Injection in Subjects With Prostate Cancer | recruiting | Phase 1 | 240 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 27, 2025 | clinicaltrials |
| NCT06850545 | Kuopio Lutetium-177 Study in Patients with PSMA-Positive Metastatic Prostate Cancer(KuPSMALu) | recruiting | — | 150 | Kuopio University HospitalOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT06844513 | Comparison Between HUGO RAS Robotic Platform and Da Vinci Robotic Platform(URO-ROBOT-2023) | not yet recruiting | N/A | 800 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06766526 | Internet-based Support for Adjustment to Prostate Cancer(ISAC) | recruiting | N/A | 180 | Linkoeping UniversityOTHER_GOV | 1 | Feb 24, 2025 | clinicaltrials |
| NCT03822494 | CyberKnife Dose Escalation Prostate Cancer Trial(CK-DESPOT) | active not recruiting | N/A | 100 | Crozer-Keystone Health SystemOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT05000827 | Dutch National Randomized Study: PSMA-PET/CT As a Triage Tool for Pelvic Lymph Node Dissection in Prostatectomy Patients(PSMA-SELECT) | recruiting | N/A | 706 | Canisius-Wilhelmina HospitalOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT06818682 | Reduced Length of ADT and ARTA With XRT in High-Risk Prostate Cancer (RELAX): A Randomised Trial(RELAX) | recruiting | Phase 2 | 206 | Tata Memorial CentreOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT06838520 | Effect of ADT and ARPI on Bone Loss of Patients with Prostate Cancer | not yet recruiting | — | 200 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT06242119 | Clinical Application of the J-PET Scanner Prototype(JPET2Clinic) | recruiting | — | 25 | Jagiellonian UniversityOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT05917860 | Neoadjuvant ADT with TULSA in the Treatment of Intermediate Risk Prostate Cancer(NeoADT-TULSA) | active not recruiting | Phase 1 | 15 | Turku University HospitalOTHER_GOV | 1 | Feb 17, 2025 | clinicaltrials |
| NCT05104515 | First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine | recruiting | Phase 1 | 36 | Oxford Vacmedix UK Ltd.INDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT06820606 | Comparing Rezum and Urolift | recruiting | N/A | 120 | Chinese University of Hong KongOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT06827080 | Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer | not yet recruiting | Phase 1 / Phase 2 | 15 | Zhengguo ChenOTHER | 0 | Feb 14, 2025 | clinicaltrials |
| NCT06828003 | Feasibility of a Remotely-Delivered Resistance Training Program for Cognitive Function in Men Living With and Beyond Prostate Cancer | not yet recruiting | N/A | 30 | University of TorontoOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT02302105 | Randomized Trial of Prostate Only or Pelvic RT in High Risk Prostate Cancer(POP-RT) | active not recruiting | N/A | 224 | Tata Memorial CentreOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT06259279 | High Impact Training to Patients with Prostate Cancer and Bone Metastases(HIP) | recruiting | N/A | 102 | Copenhagen University Hospital at HerlevOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT06612047 | Comparison of 5.0T and 3.0T Biparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer(5TbpMRI) | recruiting | — | 150 | Anhui Provincial HospitalOTHER_GOV | 1 | Feb 11, 2025 | clinicaltrials |
| NCT06737588 | The Addictive Diagnostic Value of Apparent Diffusion Coefficients to bpMRI in the Diagnosis of Prostate Cancer | recruiting | — | 600 | Anhui Provincial HospitalOTHER_GOV | 1 | Feb 11, 2025 | clinicaltrials |
| NCT06783127 | Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer(COROS) | recruiting | — | 3,000 | Santa Chiara HospitalOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT06820333 | Impact of [18F] PSMA-1007 Imaging for Primary Staging of Prostate Cancer | recruiting | — | 200 | Heinrich-Heine University, DuesseldorfOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT02176902 | Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer | active not recruiting | N/A | 107 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06449781 | 177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With High and Very High Risk Prostate Cancer(PSMA-ADJUVO) | recruiting | Phase 2 | 200 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT03763253 | Additional Treatments to the Local Tumour for Metastatic Prostate Cancer: Assessment of Novel Treatment Algorithms(IP2-ATLANTA) | active not recruiting | Phase 2 | 433 | Imperial College LondonOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT05032040 | A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies | active not recruiting | Phase 2 | 170 | Xencor, Inc.INDUSTRY | 1 | Feb 7, 2025 | clinicaltrials |
| NCT05383079 | Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer(AlphaBet) | active not recruiting | Phase 1 / Phase 2 | 36 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT04992728 | Prostate Assessment with Restriction Spectrum Imaging (RSI) MRI | recruiting | — | 100 | University of California, San DiegoOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT06785441 | Older Men's Decision Making About Active Surveillance for Prostate Cancer - Aim 3: Decision Aid Efficacy Testing | recruiting | — | 180 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 4, 2025 | clinicaltrials |
| NCT06806917 | Twenty Years' Experience in Retroperitoneal Lymph Node Dissection for Testicular Cancer in a Tertiary Referral Center | recruiting | — | 65 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Feb 4, 2025 | clinicaltrials |
| NCT05381103 | PSMA-PET to Guide Prostatectomy | recruiting | Phase 2 / Phase 3 | 288 | Five Eleven Pharma, Inc.INDUSTRY | 1 | Jan 31, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Mar 27, 2025source: clinicaltrials